Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Tourmaline Bio (TRML)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 41,310,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $ - $
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Talaris Therapeutics is a late-clinical stage, cell therapy company developing a method of allogeneic hematopoietic stem cell transplantation, called Facilitated Allo-HSCT Therapy, that has the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe blood, immune and metabolic disorders. Co.'s lead product candidate, FCR001, which is central to its Facilitated Allo-HSCT Therapy, is an allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor, who is also the organ donor in the case of organ transplantation.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 100,000 105,000 149,150 345,094
Total Buy Value $3,250,000 $3,335,270 $3,893,256 $4,632,634
Total People Bought 1 3 5 7
Total Buy Transactions 1 3 10 17
Total Shares Sold 0 0 250,003 1,062,376
Total Sell Value $0 $0 $618,955 $2,712,339
Total People Sold 0 0 1 1
Total Sell Transactions 0 0 10 28
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 89
  Page 1 of 4  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Mcdade Mark   –       •      –    2024-01-29 4 B $32.50 $3,250,000 I/I 100,000 448,431 0.01     -
   Kulkarni Sandeep Chidambar CEO   •       •      –    2023-11-17 4 B $16.99 $67,960 D/D 4,000 729,735 2.81     -
   Thiara Parvinder Director   –       •      –    2023-11-17 4 B $17.31 $17,310 D/D 1,000 83,782 2.39     -
   Castelein Caley Director   –       •      –    2023-10-27 4 B $14.55 $229,890 D/D 15,800 516,519 2.39     -
   Kulkarni Sandeep Chidambar CEO   •       •      –    2023-10-26 4 B $12.25 $61,250 D/D 5,000 725,735 2.81     -
   Castelein Caley Director   –       •      –    2023-10-25 4 B $12.07 $50,694 D/D 4,200 500,719 2.39     -
   Thiara Parvinder Director   –       •      –    2023-10-25 4 B $12.12 $24,240 D/D 2,000 82,782 2.39     -
   Kulkarni Sandeep Chidambar CEO   •       •      –    2023-10-24 4 B $10.68 $49,662 D/D 4,650 720,735 2.81     -
   Thiara Parvinder Director   –       •      –    2023-10-24 4 B $10.66 $53,300 D/D 5,000 80,782 2.39     -
   Kantoff Aaron Director   –       •      –    2023-10-24 4 B $11.86 $88,950 D/D 7,500 45,391 2.39     -
   Castelein Caley Director   –       •      –    2023-10-19 4 A $0.00 $0 I/I 458,039 458,039     -
   Castelein Caley Director   –       •      –    2023-10-19 4 A $0.00 $0 D/D 496,519 496,519     -
   Chyung Yung H. Chief Medical Officer   •       –      –    2023-10-19 4 A $0.00 $0 D/D 56,836 56,836     -
   Johnson Kevin Bruce Chief Regulatory Officer   •       –      –    2023-10-19 4 A $0.00 $0 D/D 57,834 57,834     -
   Kantoff Aaron Director   –       •      –    2023-10-19 4 A $0.00 $0 D/D 37,891 37,891     -
   Middlekauff W Bradford CBO, GC and Secretary   •       –      –    2023-10-19 4 A $0.00 $0 D/D 69,201 69,201     -
   Jones Susan Dana Chief Technology Officer   •       –      –    2023-10-19 4 A $0.00 $0 D/D 22,934 22,934     -
   Srivastava Sapna Director   –       •      –    2023-10-19 4 A $0.00 $0 D/D 518 518     -
   Kulkarni Sandeep Chidambar CEO   •       •      –    2023-10-19 4 A $0.00 $0 D/D 716,085 716,085     -
   Mcdade Mark Director   –       •      –    2023-10-19 4 A $0.00 $0 D/D 518 518     -
   Mcdade Mark Director   –       •      –    2023-10-19 4 A $0.00 $0 I/I 348,431 348,431     -
   Thiara Parvinder Director   –       •      –    2023-10-19 4 A $0.00 $0 D/D 75,782 75,782     -
   Fenton Mary Kay Chief Financial Officer   •       –      –    2023-07-03 4 D $3.08 $39,874 D/D (12,946) 68,054     -
   Requadt Scott Former Chief Executive Officer   –       –      –    2023-07-03 4 D $3.08 $36,301 D/D (11,786) 578,403     -
   Ildstad Suzanne Director   –       •      –    2023-06-14 4 S $2.49 $32,244 D/D (12,942) 3,771,392     -
  89 Records found
  1  2  3  4   
  Page 1 of 4
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us